Prognostic significance of tumor volume after radical prostatectomy: A multivariate analysis of pathological prognostic factors

European Urology

Volumn 43, Issue 1, 2003, Pages 39-44

  Salomon, Laurent ^a,b   Levrel, Olivier ^a   Anastasiadis, Aristotelis G ^b   Irani, Jacques ^a   La Taille, Alexandre De ^a   Saint, Fabien ^a   Vordos, Dimitri ^a   Cicco, Antony ^a   Hoznek, Andras ^a   Chopin, Dominique ^a   Abbou, Claude Clément ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b Coll of Phys/Surg Columbia Univ ^*  (United States)

Author keywords

Prognosis; Prostate cancer; Radical prostatectomy; Volume

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; HISTOPATHOLOGY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; SCORING SYSTEM; TUMOR VOLUME;

AGED; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 12244258221     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(02)00493-1     Document Type: Article

References (35)

1. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer specific survival following anatomic radical retropubic prostatectomy. Urol Clin North Am 2001;28:555-65.
2. Stamey TA, McNeal JE, Freiha FS, Redwine E. Morphometric and clinical studies on 68 consecutive radical prostatectomies. J Urol 1988;139:1235-41.
3. McNeal JE, Kindrachuk RA, Freiha FS, Bostwick DG, Redwine EA, Stamey TA. Patterns of progression in prostate cancer. Lancet 1986;1:60-3.
4. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with prostate cancer. JAMA 1999;281:1385-400.
5. Epstein JI, Carmichael M, Partin AW, Walsh PC. Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinoma of the prostate with 5 years of follow-up. J Urol 1993;149:1478-81.
6. Soh S, Kattan MW, Berkman S, Wheeler TM, Scardino PT. Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? J Urol 1997;157:2212-8.
7. Stamey TA, Donaldson AN, Yemoto CE, McNeal JE, Sözen S, Gill H. Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: epidemiologic significance of annual changes. J Urol 1998;60:2412-7.
8. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001;58:843-8.
9. Salomon L, Colombel M, Patard JJ, Bellot J, Vogt B, Lefrère-Belda MA, et al. Volume et représentation spatiale des tumeurs au sein de la glande prostatique. Prog Urol 1997;7:442-8.
10. TNM classification of malignant tumors: International Union Against Cancer. In: Sobin LH, Wittekind C, editors. 5th ed. New York: Wiley; 1997. p. 170-3.
11. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Urol Clin North Am 1997;24:395-406.
12. Makarov DV, Sanderson H, Partin AW, Epstein JI. Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores? J Urol 2002;167:2440-2.
13. Nelson CP, Rubin MA, Strawderman M, Montie JE, Sanda MG. Preoperative parameters for predicting early prostate cancer recurrence after radical prostatectomy. Urology 2002;59:740-5.
14. Graefen M, Karakiewicz PI, Cagiannos I, Klein E, Kupelian PA, Quinn DI. Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer. J Clin Oncol 2002;20:951-6.
15. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999;17:1499-507.
16. Lerner SE, Blute ML, Zincke H. Risks factors for progression in patients with prostate cancer treated with radical prostatectomy. Sem Urol Oncol 1996;14:12-21.
17. Ohori M, Wheeler TM, Kattan MW, Goto Y, Scardino PT. Prognostic significance of positive surgical margins in radical prostatectomy specimen. J Urol 1995;154:1818-24.
18. Wise AM, Stamey TA, McNeal JE, Clayton JL. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 2002;60:264-9.
19. Cheng WS, Frydenberg M, Bergstralh EJ, Larson-Keller JJ, Zincke H. Radical prostatectomy for pathologic stage C prostate cancer: influence of pathologic variables and adjuvant treatment on disease outcome. Urology 1993;42:283-91.
20. Barocas DA, Han M, Epstein JI, Chan DY, Trock BJ, Walsh PC, et al. Does capsular incision at radical retropubic prostatectomy affect disease-free survival in otherwise organ-confined prostate cancer? Urology 2001;58:746-51.
21. Wieder JA, Soloway MS. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. J Urol 1998;160:299-315.
22. Blute ML, Bostwick DG, Seay TM, Martin SK, Slezak JM, Bergstralh EJ, et al. Pathologic classification of prostate carcinoma: the impact of margin status. Cancer 1998;82:902-8.
23. Epstein JE. Pathologic assessment of the surgical specimen. Urol Clin North Am 2001;28:567-94.
24. Babaian RJ, Troncoso P, Steelhammer LC, Lloreta-Trull J, Ramirez EI. Tumor volume and prostate specific antigen: implications for early detection and defining a window of curability. J Urol 1995;154:1808-12.
25. Cookson MS, Fleshner NE, Soloway SM, Fair WR. Prognostic significance of prostate-specific antigen in stage T1c prostate cancer treated by radical prostatectomy. Urology 1997;49:887-93.
26. Ohori M, Wheeler TM, Dunn JK, Stamey TA, Scardino PT. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 1994;152:1714-20.
27. Douglas TH, McLeod DG, Mostofi FK, Mooneyhan R, Connely R, Moul JW, et al. Prostate-specific antigen-detected prostate cancer (stage T1c): an analysis of whole-mount prostatectomy specimens. Prostate 1997;32:59-64.
28. Humphrey PA, Keetch DW, Smith DS, Sheperd DL, Catalona WJ. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. J Urol 1996;155:816-20.
29. True LD. Surgical pathology examination of the prostate gland: practice survey by American Society of Clinical Pathologists. Am J Clin Pathol 1994;102:572-9.
30. Smith Sehdev AE, Pan CC, Epstein JI. Comparative analysis of sampling for grossing radical prostatectomy specimens performed for nonpalpable (stage T1c) prostatic adenocarcinoma. Hum Pathol 2001;32:494-9.
31. Renshaw AA, Richie JP, Loughlin KR, Jiroutek M, Chung A, D'Amico AV. The greatest dimension of prostate carcinoma is a simple, inexpensive predictor of prostate specific antigen failure in radical prostatectomy specimens. Cancer 1998;83:748-52.
32. Miller GJ, Cygan JM. Morphology of prostate cancer: the effects of multifocality on histological grade. J Urol 1994;152:1709-13.
33. Mc Neal JE. Cancer volume and site of origin of adenocarcinoma in the prostate: Relationship to local and distant spread. Hum Pathol 1992;23:258-66.
34. McNeal JE, Haillot O. Patterns of spread of adenocarcinoma in the prostate as related to cancer volume. Prostate 2001;49:48-57.
35. Salomon L, Colombel M, Patard JJ, Herard A, Chopin D, Abbou CC. Eight year improvement in pathological results after radical prostatectomy. Prostate Cancer Prostatic Dis 1999;2:21-4.